Drugs in Palliative Care

(6)
Drugs in Palliative Care image
ISBN-10:

0199660395

ISBN-13:

9780199660391

Author(s): Dickman, Andrew
Edition: 2
Released: Nov 25, 2012
Format: Paperback, 574 pages
Related ISBN: 9780199563975

Description:

While palliative care has adopted a holistic approach to treatment, medication driven symptom management ostensibly forms the critical aspect of care. Pharmacological therapy can be extremely complex because these patients often have coexisting medical conditions in addition to symptoms caused by their terminal disease. The resulting polypharmacy can be daunting for professionals and can negatively impact on effectiveness of care. Fully revised and updated, the second edition of Drugs in Palliative Care is a detailed yet concise handbook that will appeal to a variety of healthcare professionals involved in the provision of palliative care and medicines information. Divided into three sections it begins with an overview of pharmacology and prescribing advice then contains over 160 monographs of palliative care drugs, in an easy to use A-Z format.

Best prices to buy, sell, or rent ISBN 9780199660391




Frequently Asked Questions about Drugs in Palliative Care

You can buy the Drugs in Palliative Care book at one of 20+ online bookstores with BookScouter, the website that helps find the best deal across the web. Currently, the best offer comes from and is $ for the .

The price for the book starts from $32.97 on Amazon and is available from 12 sellers at the moment.

If you’re interested in selling back the Drugs in Palliative Care book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.

As for the Drugs in Palliative Care book, the best buyback offer comes from and is $ for the book in good condition.

The Drugs in Palliative Care book is in very low demand now as the rank for the book is 2,294,167 at the moment. A rank of 1,000,000 means the last copy sold approximately a month ago.

Not enough insights yet.